

MOLECULAR
HEALTH

INDIVIDUALIZED MEDICINE

DKG, BERLIN

FEBRUARY 25, 2015

HEALTHCARE IS FACING A SUBSTANTIAL PARADIGM SHIFT




With the advent of the human genome and other -omes, a transformation process has started from an

observation based knowledge medicine


to an in addition

molecular-evidence based knowledge medicine.



COMPLEXITY

IDENTIFYING PRECISE TREATMENT FOR A SINGLE PATIENT



2 micrograms of DNA




> 8,000 approved medications *



3,000,000,000 positions in human genome;
20,000 disease relevant genes



> 10,000 clinical studies *



→ infinite number of molecularly different cancers



> 23,000,000 scientific publications *

PRODUCTS



We build technology-driven products that change the way diseases can be analyzed, understood and treated.

Ongoing clinical validation studies carried out in cooperation with cancer centers worldwide, like e.g. the M.D. Anderson Cancer Center (MDACC), Houston, the NCT, Heidelberg, and other so far undisclosed partners and centers ensure that our products undergo a process of continuous validation and improvement.

NUCLEUS . KNOWLEDGE DIMENSIONS IMAGINE



... you have the entire knowledge of human genes and proteins

... you can access the entire biomedical knowledge worldwide



... you can navigate through all indications of all diseases

... you have access to all known predictive biomarkers

... you know all drugs, their mechanisms of action and their interactions without redundancy

NUCLEUS . KNOWLEDGE DIMENSIONS

IT HOLDS THE COMPLETE CURRENT BIOMEDICAL KNOWLEDGE



We offer access to the entire knowledge base of human genes and proteins.




We can navigate through all indications of all diseases currently known. We can identify all information that directly applies to patient disease and explore additional evidences for drugs and biomarkers beyond those found in the canons.

We integrate all scientific publications in the relevant areas of biomedicine, mine the text to produce our own data, and provide the links to source evidences for all major data types.




Biomarkers are essential for a precise molecular diagnosis, inherited disease risk analysis, analysis of drug toxicity risk, and treatment efficacy. We have developed the first-in-class biomarker database that holds thousands of individual evidences.



We have stored information about the molecular mechanism of action of drugs, their targets, metabolizing enzymes, drug-drug interactions and detailed drug development status.

PRODUCT MODEL . DETAIL


INTERPRETATION AND REPORTING FOR EXPERTS



Our Engines combine molecular and clinical patient data with the knowledge in Nucleus and distill the resulting information into user-friendly reports.



This Mapping is our USP



Engines refer to the knowledge in Nucleus to interpret the patients' data, aiming maximal objectiveness.



Engines distill the resulting information into comprehensive reports incl. full drill-down into details and clinical-molecular evidences for experts.

MOLECULAR HEALTH'S CODE OF DATA ETHICS



We are committed to the philosophy of privacy protection far in excess of known standards.

Molecular Health

- “ is using interpreted and outcomes data anonymously to train its treatment decision and patient safety support systems to improve the quality of treatment for the benefit of all patients.
- “ does not commercialize patients' molecular data.
- “ is committed to handle Patient Data anonymously.
- “ applies strict data protection and data privacy standards.